- Thinly traded nano cap Brainstorm Cell Therapeutics (NASDAQ:BCLI) is up 5% premarket on robust volume in response to its release of data from a Phase 2 study assessing NurOwn mesenchymal stem cells for the treatment of patients with amyotrophic lateral sclerosis (ALS).
- Treatment with NurOwn consistently beat placebo, although the difference at most time points (2 weeks - 24 weeks) fell short of statistical significance. Also the treatment effect rapidly diminished over time.
- The company plans to meet with the FDA to discuss the results. A larger confirmatory study is the next step.